Skip to content
Study details
Enrolling now

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Mayo Clinic
NCT IDNCT06972056ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

1,335

Study length

about 4.4 years

Ages

18–70

Locations

23 sites in AZ, CA, CO +15

About this study

This trial is testing the effectiveness of three migraine preventive medications: atogepant, propranolol, and topiramate. Participants will be randomly assigned to take one of these medications for 1606 days while tracking their headaches with a daily diary.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Atogepant 60 mg
  • 2.Take Propranolol 160 mg
  • 3.Take Topiramate 100 mg
PhasePhase 4
DrugAtogepant 60 mg
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

atogepant, propranolol (Non-selective beta blocker; slows heart rate), topiramate

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Medication-Related Adverse Events, Migraine Specific Quality-of-Life - Role Function-Restrictive

Body systems

Neurology